{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:01:20Z","timestamp":1772816480891,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravesical Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) is standard therapy for high-risk nonmuscle-invasive bladder cancer. However, M bovis infections can occur and are not well understood. We aimed to characterize clinical phenotypes, diagnosis, management, and outcomes of culture-confirmed M bovis BCG infections following intravesical therapy for urothelial carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective single-center review of adults with culture-confirmed M bovis infection after intravesical BCG (May 2009\u2013July 2024) was conducted, abstracting clinical, microbiologic, treatment, and outcome data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two White male patients (median age, 77 years) were included; 8 (36.4%) had localized genitourinary infection, 6 (27.3%) had dissemination limited to blood, and 8 (36.4%) had dissemination to other organs. Patients with bloodstream-only infection presented acutely (median 1.5 days after last BCG), whereas those with localized or organ-disseminated disease presented months to years after BCG, with the longest diagnostic delays in organ-disseminated infection. Despite all cases had culture-proven M bovis BCG infection, acid-fast smear, Mycobacterium tuberculosis complex polymerase chain reaction, and histopathology had limited sensitivity. All isolates were susceptible to rifampin, isoniazid, and ethambutol; all were resistant to pyrazinamide. Median treatment duration exceeded 9 months, 94.7% achieved cure, and attributable mortality was 5.0% (1 vascular graft infection).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>M bovis BCG infections following intravesical therapy have favorable outcomes but are often associated with diagnostic delays and prolonged treatment. Early suspicion, comprehensive diagnostic evaluation, and timely surgical source control when indicated are critical. Management strategies should be tailored based on the extent of disease dissemination and individual host factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag071","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:38:13Z","timestamp":1771072693000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Presentation, Management, and Outcomes of\n                    <i>Mycobacterium Bovis<\/i>\n                    Bacillus Calmette-Gu\u00e9rin (BCG) Infections: A Single-center Retrospective Review"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-0224","authenticated-orcid":false,"given":"Myeongji","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Public Health, Department of Medicine, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-5544","authenticated-orcid":false,"given":"Omar M","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Division of Public Health, Department of Medicine, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-7137","authenticated-orcid":false,"given":"Natalia E","family":"Castillo Almeida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L","family":"Wengenack","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M","family":"Deml","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-6270","authenticated-orcid":false,"given":"Isin Yagmur","family":"Comba","sequence":"additional","affiliation":[{"name":"Division of Public Health, Department of Medicine, Infectious Diseases, and Occupational Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026030605515373000_ofag071-B1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"2026030605515373000_ofag071-B2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","article-title":"Maintenance versus non-maintenance intravesical bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg"},{"key":"2026030605515373000_ofag071-B3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"2026030605515373000_ofag071-B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"2026030605515373000_ofag071-B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-024-01675-6","article-title":"Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors: a systematic review and network meta-analysis","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Urol"},{"key":"2026030605515373000_ofag071-B6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/344908","article-title":"Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy","volume":"36","author":"Gonzalez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026030605515373000_ofag071-B7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"Perez-Jacoiste Asin","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2026030605515373000_ofag071-B8","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.jctube.2020.100149","article-title":"Intravesical bacillus Calmette-Guerin (BCG) treatment's severe complications: a single institution review of incidence, presentation and treatment outcome","volume":"19","author":"Waked","year":"2020","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026030605515373000_ofag071-B9","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.5489\/cuaj.1411","article-title":"Complications of intravesical bacillus Calmette-Guerin","volume":"8","author":"Macleod","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"2026030605515373000_ofag071-B10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"2026030605515373000_ofag071-B11","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Guerin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"2026030605515373000_ofag071-B12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1066896914567332","article-title":"Histopathology of disseminated Mycobacterium bovis infection complicating intravesical BCG immunotherapy for urothelial carcinoma","volume":"23","author":"Larsen","year":"2015","journal-title":"Int J Surg Pathol"},{"key":"2026030605515373000_ofag071-B13","first-page":"366","article-title":"Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication","volume":"25","author":"Calleris","year":"2017","journal-title":"Infez Med"},{"key":"2026030605515373000_ofag071-B14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2214\/AJR.08.1962","article-title":"Imaging appearance of granulomatous disease after intravesical bacille Calmette-Guerin (BCG) treatment of bladder carcinoma","volume":"192","author":"Ma","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"2026030605515373000_ofag071-B15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12879-018-3205-7","article-title":"Bacille Calmette-Guerin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review","volume":"18","author":"Kusakabe","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026030605515373000_ofag071-B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clinimag.2020.07.016","article-title":"Osteomyelitis and septic arthritis after Mycobacterium bovis BCG therapy for urinary bladder cancer","volume":"68","author":"Lee","year":"2020","journal-title":"Clin Imaging"},{"key":"2026030605515373000_ofag071-B17","first-page":"e31697","article-title":"Systemic bacillus Calmette-Guerin infection one year after intravesical immunotherapy mimicking sarcoidosis","volume":"14","author":"Kc","year":"2022","journal-title":"Cureus"},{"key":"2026030605515373000_ofag071-B18","doi-asserted-by":"crossref","first-page":"ofaf070","DOI":"10.1093\/ofid\/ofaf070","article-title":"Mycobacterium bovis infections following intravesical bacillus Calmette-Guerin instillation for bladder cancer in western Australia: a 22-year retrospective review","volume":"12","author":"Manickavasagar","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026030605515373000_ofag071-B19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/JCM.41.4.1447-1453.2003","article-title":"Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory","volume":"41","author":"Hall","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2026030605515373000_ofag071-B20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/JCM.02128-15","article-title":"Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium species, Nocardia species, and other aerobic Actinomycetes","volume":"54","author":"Buckwalter","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2026030605515373000_ofag071-B21","doi-asserted-by":"crossref","first-page":"100340","DOI":"10.1016\/j.jctube.2022.100340","article-title":"Description, validation, and review of a decade of experience with a laboratory-developed PCR test for detection of Mycobacterium tuberculosis complex in pulmonary and extrapulmonary specimens","volume":"29","author":"Buckwalter","year":"2022","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026030605515373000_ofag071-B22","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/JCM.00467-11","article-title":"Evaluation of a single-tube multiplex real-time PCR for differentiation of members of the Mycobacterium tuberculosis complex in clinical specimens","volume":"49","author":"Halse","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2026030605515373000_ofag071-B23","volume-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes","author":"Cinical and Laboratory Standards Institute, CLSI M24","year":"2018","edition":"3rd ed"},{"key":"2026030605515373000_ofag071-B24","volume-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute, CLSI M24S","year":"2023","edition":"2nd ed,"},{"key":"2026030605515373000_ofag071-B25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/JCM.02319-10","article-title":"Xpert MTB\/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?","volume":"49","author":"Vadwai","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2026030605515373000_ofag071-B26","doi-asserted-by":"crossref","first-page":"e0180725","DOI":"10.1371\/journal.pone.0180725","article-title":"Diagnostic accuracy of Xpert MTB\/RIF for tuberculosis detection in different regions with different endemic burden: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"2026030605515373000_ofag071-B27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag071\/66971923\/ofag071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag071\/66971923\/ofag071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag071\/66971923\/ofag071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:52:00Z","timestamp":1772794320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag071\/8489497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag071","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,18]]},"article-number":"ofag071"}}